Wealth Enhancement Advisory Services LLC Has $1.94 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Wealth Enhancement Advisory Services LLC lifted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 83.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,861 shares of the medical research company's stock after buying an additional 4,483 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in IQVIA were worth $1,938,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Norges Bank bought a new position in IQVIA during the fourth quarter valued at about $336,041,000. Raymond James Financial Inc. bought a new position in IQVIA during the fourth quarter valued at about $236,120,000. American Century Companies Inc. raised its holdings in IQVIA by 396.0% during the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock valued at $222,987,000 after buying an additional 905,960 shares in the last quarter. Invesco Ltd. increased its stake in shares of IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after purchasing an additional 902,226 shares during the period. Finally, Canada Pension Plan Investment Board lifted its position in shares of IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after purchasing an additional 712,958 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. HSBC cut IQVIA from a "buy" rating to a "hold" rating and cut their price objective for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. Wall Street Zen cut IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Barclays reduced their price objective on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. Morgan Stanley increased their price objective on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and an average target price of $226.32.

IQVIA Price Performance

IQVIA stock traded up $5.55 during mid-day trading on Tuesday, hitting $159.70. 2,845,126 shares of the company were exchanged, compared to its average volume of 1,607,894. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The business has a fifty day moving average of $147.13 and a 200 day moving average of $178.43. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The company has a market capitalization of $27.63 billion, a PE ratio of 21.29, a price-to-earnings-growth ratio of 1.99 and a beta of 1.28.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the prior year, the company posted $2.54 earnings per share. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.